Rasagiline suppresses glioblastoma cell survival through oxidative stress-mediated modulation of TLR4/NF-Κb signaling and apoptosis
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains associated with poor prognosis despite multimodal treatment. The identification of clinically approved drugs with novel antitumor activities has emerged as a promising strategy for accelerating therapeutic development. Rasagiline, an...